94 related articles for article (PubMed ID: 31268585)
1. The role of CIP2A as a therapeutic target of rapamycin in radioresistant head and neck cancer with TP53 mutation.
Kim SH; Lee WH; Seong D; An JH; Je HU; Nam HY; Kim SY; Kim SW; Han MW
Head Neck; 2019 Sep; 41(9):3362-3371. PubMed ID: 31268585
[TBL] [Abstract][Full Text] [Related]
2. CIP2A is an Oct4 target gene involved in head and neck squamous cell cancer oncogenicity and radioresistance.
Ventelä S; Sittig E; Mannermaa L; Mäkelä JA; Kulmala J; Löyttyniemi E; Strauss L; Cárpen O; Toppari J; Grénman R; Westermarck J
Oncotarget; 2015 Jan; 6(1):144-58. PubMed ID: 25474139
[TBL] [Abstract][Full Text] [Related]
3. Rapalogs induce non-apoptotic, autophagy-dependent cell death in HPV-negative TP53 mutant head and neck squamous cell carcinoma.
Alam MM; Marin Fermin J; Spiller PT; Burnett C; Rong X; Moore-Medlin T; Maxwell CO; Khandelwal AR; Nathan CO
Mol Carcinog; 2022 Jan; 61(1):33-44. PubMed ID: 34598317
[TBL] [Abstract][Full Text] [Related]
4. TP53 disruptive mutations lead to head and neck cancer treatment failure through inhibition of radiation-induced senescence.
Skinner HD; Sandulache VC; Ow TJ; Meyn RE; Yordy JS; Beadle BM; Fitzgerald AL; Giri U; Ang KK; Myers JN
Clin Cancer Res; 2012 Jan; 18(1):290-300. PubMed ID: 22090360
[TBL] [Abstract][Full Text] [Related]
5. Senescence sensitivity of breast cancer cells is defined by positive feedback loop between CIP2A and E2F1.
Laine A; Sihto H; Come C; Rosenfeldt MT; Zwolinska A; Niemelä M; Khanna A; Chan EK; Kähäri VM; Kellokumpu-Lehtinen PL; Sansom OJ; Evan GI; Junttila MR; Ryan KM; Marine JC; Joensuu H; Westermarck J
Cancer Discov; 2013 Feb; 3(2):182-97. PubMed ID: 23306062
[TBL] [Abstract][Full Text] [Related]
6. Metabolic signature of squamous cell carcinoma of the head and neck: Consequences of TP53 mutation and therapeutic perspectives.
Wilkie MD; Lau AS; Vlatkovic N; Jones TM; Boyd MT
Oral Oncol; 2018 Aug; 83():1-10. PubMed ID: 30098763
[TBL] [Abstract][Full Text] [Related]
7. Copy number increase of oncoprotein CIP2A is associated with poor patient survival in human head and neck squamous cell carcinoma.
Routila J; Bilgen T; Saramäki O; Grénman R; Visakorpi T; Westermarck J; Ventelä S
J Oral Pathol Med; 2016 May; 45(5):329-37. PubMed ID: 26436875
[TBL] [Abstract][Full Text] [Related]
8. Disruption of TP63-miR-27a* Feedback Loop by Mutant TP53 in Head and Neck Cancer.
Chari NS; Ivan C; Le X; Li J; Mijiti A; Patel AA; Osman AA; Peterson CB; Williams MD; Pickering CR; Caulin C; Myers JN; Calin GA; Lai SY
J Natl Cancer Inst; 2020 Mar; 112(3):266-277. PubMed ID: 31124563
[TBL] [Abstract][Full Text] [Related]
9. CIP2A Interacts with TopBP1 and Drives Basal-Like Breast Cancer Tumorigenesis.
Laine A; Nagelli SG; Farrington C; Butt U; Cvrljevic AN; Vainonen JP; Feringa FM; Grönroos TJ; Gautam P; Khan S; Sihto H; Qiao X; Pavic K; Connolly DC; Kronqvist P; Elo LL; Maurer J; Wennerberg K; Medema RH; Joensuu H; Peuhu E; de Visser K; Narla G; Westermarck J
Cancer Res; 2021 Aug; 81(16):4319-4331. PubMed ID: 34145035
[TBL] [Abstract][Full Text] [Related]
10. CIP2A inhibits PP2A in human malignancies.
Junttila MR; Puustinen P; Niemelä M; Ahola R; Arnold H; Böttzauw T; Ala-aho R; Nielsen C; Ivaska J; Taya Y; Lu SL; Lin S; Chan EK; Wang XJ; Grènman R; Kast J; Kallunki T; Sears R; Kähäri VM; Westermarck J
Cell; 2007 Jul; 130(1):51-62. PubMed ID: 17632056
[TBL] [Abstract][Full Text] [Related]
11. Protein phosphatase 2A (PP2A) inhibitor CIP2A indicates resistance to radiotherapy in rectal cancer.
Birkman EM; Elzagheid A; Jokilehto T; Avoranta T; Korkeila E; Kulmala J; Syrjänen K; Westermarck J; Sundström J
Cancer Med; 2018 Mar; 7(3):698-706. PubMed ID: 29441695
[TBL] [Abstract][Full Text] [Related]
12. CIP2A-mediated Akt activation plays a role in bortezomib-induced apoptosis in head and neck squamous cell carcinoma cells.
Lin YC; Chen KC; Chen CC; Cheng AL; Chen KF
Oral Oncol; 2012 Jul; 48(7):585-93. PubMed ID: 22342571
[TBL] [Abstract][Full Text] [Related]
13. COTI-2, A Novel Thiosemicarbazone Derivative, Exhibits Antitumor Activity in HNSCC through p53-dependent and -independent Mechanisms.
Lindemann A; Patel AA; Silver NL; Tang L; Liu Z; Wang L; Tanaka N; Rao X; Takahashi H; Maduka NK; Zhao M; Chen TC; Liu W; Gao M; Wang J; Frank SJ; Hittelman WN; Mills GB; Myers JN; Osman AA
Clin Cancer Res; 2019 Sep; 25(18):5650-5662. PubMed ID: 31308060
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
[TBL] [Abstract][Full Text] [Related]
15. FL118 inhibits viability and induces apoptosis of colorectal cancer cells via inactivating the CIP2A/PP2A axis.
Lin X; Gao M; Zhang A; Tong J; Zhang X; Su Q; Yang Z; Gao H; Jiang G
Life Sci; 2019 Dec; 239():117074. PubMed ID: 31751585
[TBL] [Abstract][Full Text] [Related]
16. Mevalonate pathway activity as a determinant of radiation sensitivity in head and neck cancer.
Ricco N; Flor A; Wolfgeher D; Efimova EV; Ramamurthy A; Appelbe OK; Brinkman J; Truman AW; Spiotto MT; Kron SJ
Mol Oncol; 2019 Sep; 13(9):1927-1943. PubMed ID: 31225926
[TBL] [Abstract][Full Text] [Related]
17. Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence.
Osman AA; Monroe MM; Ortega Alves MV; Patel AA; Katsonis P; Fitzgerald AL; Neskey DM; Frederick MJ; Woo SH; Caulin C; Hsu TK; McDonald TO; Kimmel M; Meyn RE; Lichtarge O; Myers JN
Mol Cancer Ther; 2015 Feb; 14(2):608-19. PubMed ID: 25504633
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of different response to ionizing irradiation in isogenic head and neck cancer cell lines.
Todorovic V; Prevc A; Zakelj MN; Savarin M; Brozic A; Groselj B; Strojan P; Cemazar M; Sersa G
Radiat Oncol; 2019 Nov; 14(1):214. PubMed ID: 31775835
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic regulation of p62/SQSTM1 overcomes the radioresistance of head and neck cancer cells via autophagy-dependent senescence induction.
Lee M; Nam HY; Kang HB; Lee WH; Lee GH; Sung GJ; Han MW; Cho KJ; Chang EJ; Choi KC; Kim SW; Kim SY
Cell Death Dis; 2021 Mar; 12(3):250. PubMed ID: 33674559
[TBL] [Abstract][Full Text] [Related]
20. Effect of complementary pathway blockade on efficacy of combination enzastaurin and rapamycin.
Liu J; Kuo WL; Seiwert TY; Lingen M; Ciaccio MF; Jones RB; Rosner MR; Cohen EE
Head Neck; 2011 Dec; 33(12):1774-82. PubMed ID: 21438065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]